AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05612243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of a meal with yogurt enriched with probiotics immobilized on oat flakes
Description: Participants will consume a meal including 200g of yogurt with Lacticaseibacillus rhamnosus probiotics (3\*10\^9 cfu/g) immobilized on oat flakes (1g), as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
Study NCT04759144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CamAPS FX using faster insulin aspart
Description: CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data
Study NCT04759144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CamAPS FX using standard insulin aspart
Description: CamAPS FX closed loop system comprises:~* Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~* Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~* An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~* Cloud upload system to monitor CGM/insulin data
Study NCT05612243 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Consumption of a meal with plain Yogurt with oat flakes
Description: Participants will consume a meal including 200g of plain yogurt containing 1g of oat flakes, as a placebo, as well as two slices of white bread (80g) with butter (30g). Then blood biomarkers will be examined to determine the effect of probiotic-enriched yogurt on postprandial glycemia and lipemia.
Study NCT06281717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Endotracheal Occlusion (FETO)
Description: The FETO insertion procedure will be performed between gestational age 27 weeks 0 days and 29 weeks and 6 days. The Goldballoon Detachable Balloon (GOLDBAL2) will be inserted in the airway of the fetus using the Delivery Microcatheter (BALTACCI-BDPE100). The fetal tracheal balloon will be removed between 34 weeks 0 days and 34 weeks 6 days gestation or earlier as indicated.
Study NCT06628596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Paraxanthine 200mg and 300mg
Description: Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.
Study NCT06628596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Paraxanthine 200mg and 300mg
Description: Participants consumed 200 mg paraxanthine (PXN 200), 300 mg paraxanthine (PXN 300), or placebo (PLA) after an overnight fast. Supplements were ingested 30 minutes before a mixed meal in double-blind, randomized, placebo-controlled, crossover fashion.
Study NCT06630923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human albumin
Description: Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
Study NCT06630923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin
Description: Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.
Study NCT05809076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tACS
Description: tACS is a non-invasive method to induce brain modulation. It will be applied at a frequency of 40 Hz (gamma-tACS) with a peak-to-peak intensity of 2 mA. During the real tACS condition, the alternating current will be administered for 20 minutes.
Study NCT05809076 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tACS
Description: In the sham tACS condition, the current will be delivered only for the first 30 seconds and then stopped, in order to simulate the same somatosensory sensations as real tACS, but without inducing modulation.
Study NCT03960255 — intervention group
Intervention type: OTHER
Intervention: Normal standard care
Description: Both groups will receive standardized treatment and care for diabetic foot ulcers
Study NCT06050369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: Recording, from the scalp, the electrophysiological activity of the brain.
Study NCT06050369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Get the anatomical shape of the brain.
Study NCT04859777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPT-0118
Description: MPT-0118 is an inhibitor of MALT1 protease
Study NCT04859777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPT-0118 + pembrolizumab
Description: MPT-0118 is an inhibitor of MALT1 protease; pembrolizumab is a PD-1 inhibitor
Study NCT05431660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education and exercise protocol about diabetic foot
Description: In diabetic foot school education, foot anatomy and functions, biomechanics, diabetic foot causes, epidemiology, causes of pain will be explained and treatment methods, ergonomic information, exercises to be done, sensory education, appropriate positions in daily life activities, risky situations, points to be considered and foot care. information will be given.
Study NCT05431660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: diabetic foot school information booklet and weekly video conference meeting
Study NCT05072782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab CT-P13
Description: Stratification 1: Infliximab-CT-P13~Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors
Study NCT05072782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Immunosuppressors (Thiopurines or Methotrexate)
Description: Stratification 1 : No treatments~Stratification 2 : Immunosuppressors at same dose
Study NCT06436261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.
Study NCT06436261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Fractional Laser
Description: A hybrid fractional HALO™ laser treatment was performed after a 7-day washout period. Subjects were numbed for 30 minutes to 1 hour prior to the procedure with a topical numbing cream containing benzocaine, lidocaine, and/or tetracaine. After numbing was completed, patients received one full-face HALO™ laser treatment with settings 350/20/20.
Study NCT06436261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Cleanser
Description: Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.
Study NCT06436261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Cleanser
Description: Subjects were to use the provided cleanser twice daily (morning and evening) during the 7-day washout period and 7-day post-procedure timeline.
Study NCT06436261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial Moisturizer
Description: Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon).
Study NCT06436261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial Moisturizer
Description: Subjects were to use the provided bland facial moisturizer as follows:~WASHOUT PERIOD (7 days): After cleansing, 1-2 pumps were to be applied twice daily (morning and evening) to the full face avoiding the eye area~POST-PROCEDURE (7 days): After applying the Post-Procedure Cream and Active Comparator based on split-face randomization, the facial moisturizer was to be applied twice daily (morning and afternoon).
Study NCT06436261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.
Study NCT06436261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: During the 7-day washout period and 7-day post-procedure timeline, subjects were to apply the provided basic sunscreen in the morning and afternoon after applying facial moisturizer. Sunscreen was to be reapplied as needed throughout the day per FDA recommendations.
Study NCT05847361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BH4 blood level
Description: from admission to END OF PREGNANCY, a blood sample is taken.
Study NCT05176353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAP diagnostic stewardship bundle
Description: Multifaceted VAP diagnostic stewardship bundle targeting the respiratory culture testing workflow through a custom order set within the institutional electronic medical record. Interventions will be made at the three levels of the diagnostic testing pathway (ordering, collection and reporting of test results). Full details available in detailed study description.
Study NCT04934228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5Mg Tab
Description: Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)~Planned use in this study~1. Condition/disease indication(s): Hypertension~2. Subject population: Hypertension~3. Dose(s): 25 mg/day~4. Administration: Oral~5. Dosing regimen: 12.5 mg twice per day
Study NCT04934228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice/day)~Planned use in this study~1. Condition/disease indication(s): Vascular function and blood flow~2. Subject population: Hypertension~3. Dose(s): 0.1 mg (oral)~4. Administration: Oral~5. Dosing regimen: 0.1 mg twice daily by mouth
Study NCT04934228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.
Study NCT05925712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroFit Seal-In Liner / Socket
Description: Össur AeroFit® solution is a transfemoral breathable prosthetic interface, combining the AeroFit® Seal-In liner and AeroFit® Socket.
Study NCT05925712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-In Silicone Liner
Description: Seal-In Silicone Lineris transfemoral prosthetic interface used in combination with a prosthetic socket system.
Study NCT06351631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: 10, 15, 20, and 50 mg oral capsules
Study NCT05039736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by PO
Study NCT05039736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV
Study NCT06323330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech rehabilitation
Description: Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase
Study NCT06323330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech rehabilitation
Description: Melodic Intonation Therapy- Indian Adaptation module which will be developed in the pilot phase
Study NCT05165914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous midazolam before emergence from general anesthesia
Description: Intravenous administration of 0.03 mg/kg midazolam just before emergence from anesthesia.
Study NCT05165914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline before emergence from general anesthesia
Description: Intravenous administration of normal saline just before emergence from anesthesia.
Study NCT06625060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200
Description: Lyophilised powder
Study NCT06625060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients without active substance, Lyophilised powder
Study NCT06625060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200 dose A
Description: Lyophilised powder
Study NCT06625060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPN10200 dose B
Description: Lyophilised powder
Study NCT06684626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate (Butirprost®) is a nutraceutical formulation in suppository form, designed for the management of chronic bacterial prostatitis (CBP). It contains key ingredients such as sodium hyaluronate, a derivative of hyaluronic acid (HA), along with Plantago major. Sodium hyaluronate is valued for its potent anti-inflammatory and tissue-regenerative properties, while Plantago major offers additional benefits through its soothing and wound-healing effects, enhancing the overall efficacy of the formulation in treating CBP.
Study NCT04878757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CFI - Classwide Fraction Intervention
Description: 40 sessions (2 sessions per week; 25-31 minutes per session) of explicit fraction intervention designed to improve students understanding of fraction magnitude and fraction operations.
Study NCT05976633 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole white rice (control)
Description: One serving size (140g cooked on stovetop) of whole white rice will be provided. Cooking time will be consistently maintained throughout.
Study NCT05976633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole brown rice
Description: One serving size (140g cooked on stovetop) of whole brown rice will be provided. Cooking time will be consistently maintained throughout.
Study NCT05976633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole wild rice
Description: One serving size (140g cooked on stovetop) of whole wild rice will be provided. Cooking time will be consistently maintained throughout.
Study NCT05976633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15% Wild rice and 85% Brown rice blend - Stovetop
Description: One serving size (140g cooked on stovetop) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
Study NCT05101642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Creeping Technique (GCT)
Description: Guided Creeping Technique (GCT) is a novel minimally invasive blind tunnel
Study NCT05522452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation program: Intervention will be applied by video interview for 12 weeks, 2 days a week, 45 minutes a day through the Zoom application. The application is free and can be installed on desktop or laptop computers, tablets and smartphones. The content of the activities to be done for that session by phone call to the parent before the interventions; Information will be given about the preparations such as keeping the materials on the table, suitable environment for that week's session and camera angle. Instructions and tips for parent support during the intervention will be given before and during the session. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
Study NCT05522452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face to face rehabilitation
Description: Face to face program: Intervention will be applied by physiotherapist for 12 weeks, 2 days a week, 45 minutes a day in clinic. Intervention will be focused on upper extremity skills and activities of daily life of the individuals.
Study NCT06260813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Radiography
Description: X-rays of the ankle; anterior-posterior, lateral, Mortise view and hindfoot alignment view. Standard weight bearing x-rays of the foot; anterior-posterior, lateral and oblique view.
Study NCT06260813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound of the posterior tibial tendon to see if there is an irritation, elongation or rupture.
Study NCT06260813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI when ultrasound is not conclusive to identify an irritation, elongation or rupture of the posterior tibial tendon.
Study NCT06260813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT-scan
Description: CT-scan to identify arthritis of the tibial-talar, subtalar and/or Chopart joints.
Study NCT06260813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: This lab is equipped with a 10-meter walkway surrounded by a passive optoelectronic motion analysis system consisting of 10 cameras to track the motion of markers. In the middle of the walkway, a force plate is integrated, with a pressure plate placed on top.
Study NCT05158608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-transplantation Cyclophosphamide at dose 25 mg/kg/day
Description: Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
Study NCT05158608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
Description: Post-transplantation Cyclophosphamide will be apply for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
Study NCT05976633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15% Wild rice and 85% Brown rice blend - Microwaved
Description: One serving size (140g cooked in microwave) of 15% wild rice and 85% brown rice blend (Myera) will be provided. Cooking time will be consistently maintained throughout.
Study NCT06377748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated tucking position
Description: Neonates in this group will be given facilitated tucking position (lower and upper extremities will be held in right lateral flexion position and midline) by a volunteer nurse one minute before the vaccination procedure. The nurse will administer intramuscular vaccine injection into the vastus lateralis region of the left leg of the infant in the facilitated tucking position according to routine practice.
Study NCT06377748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: Immediately prior to the vaccination procedure, the nurse will place the protruding surface of the ShotBlocker on the neonate's vaccination procedure site (left leg vastus lateralis muscle). The nurse will continue to hold the ShotBlocker at the injection site by pressing against the skin for 20 seconds. At the end of the time, she will grasp the tissue with the ShotBlocker and inject the vaccine through the opening in the center. After the procedure is completed and the needle is withdrawn, the ShotBlocker will be removed from the skin.
Study NCT06282835 — intervention group
Intervention type: DRUG
Intervention: Eravacycline Injection
Description: Eravacycline at the recommended dose and administration method according to the instructions: 1 mg/kg intravenous administration, every 12 hours. The intravenous infusion duration is approximately 60 minutes. For patients with severe liver impairment (Child-Pugh class C), administer 1 mg/kg of this product every 12 hours on the first day, followed by 1 mg/kg every 24 hours starting from the second day.
Study NCT05482386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin discontinuation
Description: Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.